<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Infliximab has demonstrated remarkable effects on controlling <z:hpo ids='HP_0000554'>uveitis</z:hpo> in patients with <z:chebi fb="6" ids="22696">Beh</z:chebi>Ã§et's disease (BD) </plain></SENT>
<SENT sid="1" pm="."><plain>However, there is no way except for discontinuation of infliximab treatment in patients who are intolerant to the agent due to hypersensitivity reactions </plain></SENT>
<SENT sid="2" pm="."><plain>We here report successful switching from infliximab to adalimumab in a BD patient </plain></SENT>
<SENT sid="3" pm="."><plain>Treatment with infliximab had maintained clinical remission in the patient having refractory ocular lesions to <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> until the patient had experienced repeated infliximab-related infusion reactions </plain></SENT>
<SENT sid="4" pm="."><plain>Discontinuation of the therapy led to another ocular attacks immediately </plain></SENT>
<SENT sid="5" pm="."><plain>Switching to adalimumab induced clinical remission again </plain></SENT>
<SENT sid="6" pm="."><plain>Our experience suggest adalimumab is a safe and effective option for patients having hypersensitivity to infliximab </plain></SENT>
</text></document>